ScholarIQanswers from OpenAlex & ORCID
Mariano Provencio
ResearcherPublications, citations & collaboration network
Mariano Provencio is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Mariano Provencio have?
ScholarIQindexed works
Mariano Provencio has 976 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Mariano Provencio have?
ScholarIQcitation count
Mariano Provencio has 28,329 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Mariano Provencio?
ScholarIQh-index
Mariano Provencio has an h-index of 71 in OpenAlex.
What is the i10-index of Mariano Provencio?
ScholarIQi10-index
Mariano Provencio has an i10-index of 308 in OpenAlex.
What is the ORCID of Mariano Provencio?
ScholarIQorcid
The ORCID for Mariano Provencio is on the source record.
What is the OpenAlex record for Mariano Provencio?
ScholarIQopenalex
The OpenAlex for Mariano Provencio is on the source record.
What are the most-cited papers on Mariano Provencio?
ScholarIQmost cited works
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell, Enric Carcereny, Radj Gervais, A. Vergnenègre, Bartomeu Massutí, Enriqueta Felip, Ramón Palmero, Ramón García-Gómez, Cinta Pallarés, José Miguel Sánchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Morán, Amelia Insa, Filippo de Marinis, R. Corre, Isabel Bover, Alfonso Illiano, Éric Dansin, Javier de Castro, Michèle Milella, Noemı́ Reguart, Giuseppe Altavilla, Ulpiano Jiménez, Mariano Provencio, Miguel Ángel Moreno, Josefa Terrasa, José Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Dómine, Olivier Molinier, Julien Mazières, Nathalie Baize, Rosario García‐Campelo, G. Robinet, Delvys Rodríguez‐Abreu, Guillermo López-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, P. Bombaron, Reyes Bernabé, Alessandra Bearz, Á. Artal, Enrico Cortesi, Christian Rolfo, María Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, José Luis Ramírez, José Javier Sánchez, Miguel Ángel Molina‐Vila, Miquel Tarón, Luis Paz‐Ares
Perioperative Nivolumab in Resectable Lung Cancer
Tina Cascone, Mark M. Awad, Jonathan Spicer, Jie He, Shun Lü, Boris Sepesi, Fumihiro Tanaka, Janis M. Taube, Robin Cornelissen, Libor Havel, Nina Karaseva, Jarosław Kużdżał, Luboš Petruželka, Lin Wu, Jean-Louis Pujol, Hiroyuki Ito, Tudor–Eliade Ciuleanu, Ludmila de Oliveira Muniz Koch, Annelies Janssens, Aurelia Alexandru, Sabine Bohnet, Fedor V. Moiseyenko, Yang Gao, Yasutaka Watanabe, Cinthya Coronado Erdmann, Padma Sathyanarayana, S. Meadows–Shropshire, Steven I. Blum, Mariano Provencio
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy
William D. Travis, Sanja Đačić, Ignacio I. Wistuba, Lynette M. Sholl, Prasad S. Adusumilli, Lukas Bubendorf, Paul A. Bunn, Tina Cascone, Jamie E. Chaft, Gang Chen, Teh‐Ying Chou, Wendy A. Cooper, Jeremy J. Erasmus, Carlos Gil Ferreira, Jin-Mo Goo, John V. Heymach, Fred R. Hirsch, Hidehito Horinouchi, Keith M. Kerr, Mark G. Kris, Deepali Jain, Young Tae Kim, Fernando López‐Ríos, Shun Lü, Tetsuya Mitsudomi, André Moreira, Noriko Motoi, Andrew G. Nicholson, Ricardo Oliveira, Mauro Papotti, Ugo Pastorino, Luis Paz‐Ares, Giuseppe Pelosi, Claudia Poleri, Mariano Provencio, Anja C. Roden, Giorgio V. Scagliotti, Stephen G. Swisher, Erik Thunnissen, Ming‐Sound Tsao, Johan Vansteenkiste, Walter Weder, Yasushi Yatabe
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu, Jong-Seok Lee, László Urbán, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Clarisse Audigier-Valette, Jacobus A. Burgers, Adam Płużański, Randeep Sangha, Carlos Gallardo, Masayuki Takeda, Helena Linardou, Lorena Lupinacci, Ki Hyeong Lee, Claudia Caserta, Mariano Provencio, Enric Carcereny, Gregory A. Otterson, Michael Schenker, Bogdan Żurawski, Aurelia Alexandru, A. Vergnenègre, Judith Raimbourg, Kynan Feeney, Sang‐We Kim, Hossein Borghaei, Kenneth J. O’Byrne, Matthew D. Hellmann, Arteid Memaj, Faith E. Nathan, Judith Bushong, Phuong Tran, Julie R. Brahmer, Martin Reck
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Martin Reck, Michael Schenker, Ki Hyeong Lee, Mariano Provencio, Makoto Nishio, Krzysztof Leśniewski-Kmak, Randeep Sangha, Samreen Ahmed, Judith Raimbourg, Kynan Feeney, R. Corre, Fábio Franke, Eduardo Richardet, John R. Penrod, Yong Yuan, Faith E. Nathan, Prabhu Bhagavatheeswaran, Michael DeRosa, Fiona Taylor, Rachael Lawrance, Julie R. Brahmer